Sanofi Q3 sales boosted by Dupixent, Vaccines business; raises FY22 outlook again

Oct. 28, 2022 5:09 AM ETRegeneron Pharmaceuticals, Inc. (REGN), SNYBy: Ravikash, SA News Editor1 Comment

Sanofi Distribution Centre in Kirkland, Quebec, Canada.

JHVEPhoto

Sanofi (NASDAQ:SNY) Q3 sales grew on the performance of its blockbuster drug Dupixent and Vaccines business, while the company also raised its FY22 business EPS outlook.

Q3 Business EPS rose +32.1% Y/Y (reported basis) (+17.9% at constant exchange rates, or CER) to €2.88

Recommended For You

Comments (1)

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.